OvaScience Reports Third Quarter 2017 Financial Results
– Initial Safety Data from First 20 Patients in OvaPrime℠ Clinical Trial Expected by Year-End –
– Granted Exclusive License to
– Conference Call Today at
“This quarter we focused on accelerating the pace and efficiency of our
ongoing research and development efforts and on creating robust and
compelling preclinical and clinical data for our treatments,” said Dr.
Third Quarter and Recent Business Highlights:
OvaPrime℠ Treatment: OvaPrime is a potential fertility treatment that could help a woman who makes too few or no eggs by transferring her own concentrated egg precursor (EggPC℠) cells to a different region in her own ovary, where they may mature into fertilizable eggs.
OvaSciencecontinues to progress its ongoing single center, prospective, blinded and placebo-controlled study of OvaPrime, which is designed to assess the treatment’s safety in women with either primary ovarian insufficiency or poor ovarian response. Additional exploratory endpoints include OvaPrime’s effect on patients’ anti-mullerian hormone, follicle stimulating hormone and estradiol levels, as well as follicular development as measured by ultrasound. The Company plans to use the results of this study to inform the future clinical development of OvaPrime.
OvaScienceincreased the modified intent-to-treat (mITT) population in the OvaPrime safety study from 50 to 70 in order to include a greater number of subjects with primary ovarian insufficiency. As a result, the enrollment for this study was increased to 95. To date, the Company has enrolled 78 patients. OvaScienceexpects to complete biopsies in 70 patients and to announce initial safety data from the first 20 patients by year-end.
OvaTure℠ Treatment: OvaTure is a potential fertility treatment that could help a woman produce healthy, fertilizable eggs without hormone injections by maturing EggPC cells into eggs in vitro.
Under the OvaTure collaboration,
OvaScienceand Intrexoncontinued to optimize culture conditions for the maturation of human and bovine EggPC cells and introduced new analytical assays into the process to further characterize maturing eggs that are ideal candidates for future fertilization studies. In parallel, the companies are exploring additional bovine fertilization strategies for EggPC cell-derived eggs – in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). OvaSciencepreviously communicated a goal of fertilizing a bovine EggPC cell-derived egg in 2017. While the companies are rigorously advancing several different experimental approaches that will read-out by year-end, there is no certainty that these ongoing efforts will result in a fertilized bovine egg this year. OvaScienceremains firmly committed to advancing the OvaTure program and will provide regular updates as efforts progress.
OvaSciencecontinues to work with its academic partners toward securing authorization to fertilize human EggPC cell-derived eggs.
AUGMENT℠ Treatment: AUGMENT is a fertility treatment designed to improve egg fertilization efficiency and IVF success rates, by using mitochondria from a woman’s own EggPC cells during IVF.
October 2017, OvaSciencegranted an exclusive license to IVF Japan Group, a clinic network with significant AUGMENT experience, to offer the treatment in Japan. This will enable IVF Japan Groupto generate additional outcomes data and to help inform the target patient profile for the treatment. Under the terms of the agreement, OvaSciencewill incur minimal expense. IVF Japan Groupwill pay OvaSciencea fixed amount per AUGMENT cycle that will cover all lab operations and personnel costs. OvaSciencewill retain worldwide commercialization rights for AUGMENT outside of Japanand will continue ongoing operations related to the AUGMENT treatment in North America.
Third Quarter 2017 Financial Results:
Research and development expense for the quarter, excluding
restructuring charges, was
$4.0 million, compared to $5.0 millionfor the same period in 2016. This decrease was primarily driven by decreased employee related costs, including stock-based compensation expense mostly due to restructuring activities.
Selling, general and administrative expense for the quarter, excluding
restructuring charges, was
$5.1 million, compared to $12.6 millionfor the same period in 2016. This decrease was driven by reduced employee related costs, including stock-based compensation expense and commercial related activities mostly due to restructuring activities.
Net loss for the quarter was
$9.4 million, or $0.26per share, compared to a net loss of $19.3 million, or $0.54per share, for the same period in 2016. The net loss for the quarter includes restructuring charges of $0.4 million.
The cash outlays related to the restructurings in the third quarter of
This press release includes forward-looking statements about the Company’s plans for the OvaPrime℠ treatment, OvaTure℠ treatment and AUGMENT℠ treatment, including statements relating to the Company’s (i) belief that it will complete of biopsies in 70 patients in the ongoing Canadian OvaPrime study and have initial data readout from 20 patients in the Canadian study by the end of 2017, (ii) plans for additional enrollment in the OvaPrime study, (iii) expectations relating to its AUGMENT license with IVF Japan, including anticipated data and anticipated minimal expense to the Company, , (iv) plans for the bovine and human OvaTure program, and the goal of fertilizing a bovine Egg PC-cell derived egg and (iv) plans to develop a repeatable and robust process for the maturation of human EggPC cells and to pursue authorization to fertilize human EggPC cell-derived eggs. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the science underlying our treatments (including the OvaPrime, OvaTure and AUGMENT treatments), which is unproven; our ability to obtain regulatory approval or licenses where necessary for our treatments; our ability to develop our treatments on the timelines we expect, if at all; our ability to commercialize our treatments, on the timelines we expect, if at all; risks associated with clinical and other studies; development risk; risks associated with dependence on third parties, including our partners; operational risks; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.
-- Financial Tables to Follow --
|Condensed Consolidated Balance Sheets|
|Cash and cash equivalents||$||24,775||$||43,930|
|Prepaid expenses and other current assets||1,871||2,056|
|Total current assets||77,607||116,444|
|Property and equipment, net||3,606||5,572|
|Investment in joint venture||0||65|
|Other long-term assets||24||24|
|Liabilities and stockholders’ equity|
|Accrued expenses and other current liabilities||6,203||11,026|
|Total current liabilities||8,902||13,209|
|Other non-current liabilities||834||1,116|
|Total stockholders’ equity||72,289||108,217|
|Total liabilities and stockholders’ equity||$||82,025||$||122,543|
|Condensed Consolidated Statements of Operations|
|(In thousands, except per share data)|
Three Months Ended
Nine Months Ended
|Costs and expenses:|
|Cost of revenues||29||1,559||593||3,968|
|Research and development||4,016||4,990||14,777||16,932|
|Selling, general and administrative||5,056||12,612||22,935||38,276|
|Total costs and expenses||9,462||19,161||42,148||59,176|
|Loss from operations||(9,406||)||(18,964||)||(41,944||)||(58,644||)|
|Interest income, net||(192||)||(162||)||(561||)||(497||)|
|Other income, net||3||33||37||83|
|Loss from equity method investment||140||364||1,015||1,171|
|Loss before income taxes||$||(9,356||)||$||(19,199||)||$||(42,436||)||$||(59,400||)|
|Income tax expense||11||92||34||217|
|Net loss per share—basic and diluted||$||(0.26||)||$||(0.54||)||$||(1.19||)||$||(1.92||)|
|Weighted average number of shares used in net loss per share—basic and diluted||35,687||35,568||35,664||30,985|
Jennifer Viera, 617-420-8728